← Back to Search

PulsePoint App for Cardiac Arrest

N/A

Recruiting

Led By John M Tallon, MD MSc

Research Sponsored by Dr. Steven Brooks

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with 911 calls assigned as "suspected" or "confirmed" cardiac arrest and, Are confirmed to be EMS-treated, public location out-of-hospital cardiac arrest.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up this will be tracked for each notification event that occurs during the anticipated 2 year accrual time frame.

Awards & highlights

Study Summary

This trial will test whether an app that alerts bystanders of a nearby cardiac arrest can increase the rate of CPR or defibrillator use.

Who is the study for?

The PulsePoint Study is for patients who experience a non-traumatic, out-of-hospital cardiac arrest in public. They must be treated by EMS and have their condition confirmed as 'suspected' or 'confirmed' cardiac arrest. It excludes those with traumatic arrests, arrests at dangerous scenes, EMS-witnessed events, cases not treated by EMS (like DNRs), or incidents in nursing homes/healthcare facilities.Check my eligibility

What is being tested?

This study tests if the PulsePoint system can increase bystander CPR or defibrillator use when someone has a cardiac arrest in public. Participants are randomly divided into two groups: one receives PulsePoint alerts plus standard dispatch; the other gets only standard dispatch.See study design

What are the potential side effects?

Since this trial involves an alert system rather than a medical intervention, there are no direct side effects from drugs or treatments to list.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I had a cardiac arrest in a public place and was treated by EMS.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ this will be tracked for each notification event that occurs during the anticipated 2 year accrual time frame.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~this will be tracked for each notification event that occurs during the anticipated 2 year accrual time frame.

This trial's timeline: 3 weeks for screening, Varies for treatment, and this will be tracked for each notification event that occurs during the anticipated 2 year accrual time frame. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients receiving bystander resuscitation

Secondary outcome measures

EMS on scene time interval (secondary safety outcome)

EMS response time interval (secondary safety outcome)

False positive rate for PulsePoint activation (secondary system performance outcome)

+10 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Conventional Emergency Dispatch PLUS PulsePoint notificationExperimental Treatment1 Intervention

Eligible 911 calls randomized to the experimental arm of the study will undergo usual dispatch of emergency services personnel as per pre-existing local protocols and activation of the PulsePoint system. When triggered, the system will push location data to all PulsePoint mobile application users within 400 meters of the emergency. Devices receiving the alerts from the PulsePoint system will alarm with auditory, tactile and visual stimuli. The application will present a map showing the exact location of the emergency and the closest public access defibrillator.

Group II: Conventional Emergency DispatchActive Control1 Intervention

Patients randomized to the control arm will receive conventional emergency medical dispatching procedures as per pre-existing local protocols (e.g. dispatch of emergency vehicles, attempted dispatch-assisted CPR) without activation of the PulsePoint system. 911 calls randomized to the control arm will not be associated with any PulsePoint alerts.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dr. Steven BrooksLead Sponsor

University of TorontoOTHER

690 Previous Clinical Trials

1,019,121 Total Patients Enrolled

1 Trials studying Cardiac Arrest

128 Patients Enrolled for Cardiac Arrest

Columbus Division of FireUNKNOWN

Media Library

PulsePoint notification Clinical Trial Eligibility Overview. Trial Name: NCT04806958 — N/A

Cardiac Arrest Research Study Groups: Conventional Emergency Dispatch PLUS PulsePoint notification, Conventional Emergency Dispatch

Cardiac Arrest Clinical Trial 2023: PulsePoint notification Highlights & Side Effects. Trial Name: NCT04806958 — N/A

PulsePoint notification 2023 Treatment Timeline for Medical Study. Trial Name: NCT04806958 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people are being monitored for this research endeavor?

"This medical trial requires 522 applicants that fulfill the eligibility requirements. Those wishing to join can go to one of many sites, including Columbus Division of Fire in Ohio and Winnipeg Fire Paramedic Service in Manitoba."

Answered by AI

Is enrollment open for this research endeavor?

"Affirmative. Clinicaltrials.gov data indicates that the trial, which was initially made public on June 8th 2021, is actively seeking enrolment from 522 participants from 3 different sites."

Answered by AI